8-K: BioLife Solutions Reports Strong Q2 Results, Raises Full-Year Revenue Guidance

BioLife Solutions announced positive second-quarter results, including an 11% sequential increase in cell processing revenue and an improved full-year revenue outlook.

Summary

• BioLife Solutions reported its second-quarter 2024 financial results, showing a total revenue of $28.3 million, a 3% decrease year-over-year but a 6% increase sequentially.
• The Cell Processing platform revenue reached $18.0 million, down 4% year-over-year but up 11% sequentially.
• Biostorage Services revenue was $7.0 million, a slight increase year-over-year but a 2% decrease sequentially.
• Freezers and Thaw Systems revenue was $3.4 million, down 7% year-over-year and 4% sequentially.
• The company's GAAP gross margin was 51%, and the non-GAAP adjusted gross margin was 52%.
• GAAP net loss from continuing operations was $7.1 million, which includes a $4.1 million write-off of an equity investment.
• Non-GAAP adjusted EBITDA was $4.8 million, or 17% of revenue.
• BioLife Solutions raised its full-year 2024 total revenue guidance to $99.0 million to $101.0 million and Cell Processing revenue guidance to $70.0 million to $71.0 million.
• The company processed 12 new U.S. FDA Master File cross-references for its biopreservation media, bringing the cumulative total to 728.
• BioLife's biopreservation media is now embedded in 15 unique commercial CGTs, with an expectation of 11 additional approvals or expansions in the next 12 months.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with improved financial metrics and raised guidance, although there are some year-over-year revenue declines and a net loss. The positive momentum and strategic alignment with the CGT market contribute to a favorable sentiment.

Positives

• The business has stabilized, and momentum continues with the third consecutive quarter of sequential revenue growth.
• The company is benefiting from the strength of its high-margin, recurring, and consumable product offerings.
• There is notable expansion in gross margin and increased adjusted EBITDA.
• The company is strategically aligned with favorable secular trends in cell and gene therapies.
• BioLife's biopreservation franchise supports more than 70% of U.S. commercial CGT trials.
• Management expects full-year positive adjusted EBITDA and adjusted EBITDA growth in 2024.
• The sale of the GCI freezer division was completed in April, streamlining the business.

Negatives

• Total revenue for the second quarter decreased by 3% year-over-year.
• Cell Processing platform revenue decreased by 4% year-over-year.
• Freezers and Thaw Systems platform revenue decreased by 7% year-over-year.
• The company reported a GAAP net loss from continuing operations of $7.1 million, including a $4.1 million write-off.
• Cash, cash equivalents, and marketable securities decreased to $36.9 million as of June 30, 2024.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's non-GAAP financial measures may not be comparable to those of other companies.
• The company's revenue guidance is based on expectations and may not be achieved.
• The company's business is subject to the risks associated with the cell and gene therapy market.

Future Outlook

Management expects full-year positive adjusted EBITDA and adjusted EBITDA growth in 2024. The company has raised its full-year revenue guidance based on expectations for its Cell Processing and Biostorage Services platforms.

Management Comments

• We are pleased with our second quarter results. The business has stabilized and momentum continues with our third consecutive quarter of sequential revenue growth.
• With our continued focus on streamlining the business, we are now beginning to benefit from the strength of our high margin, recurring and consumable product offerings.
• Our focus on our core cell processing product platform is emerging in our financial performance, with notable expansions in gross margin, increased adjusted EBITDA, and encouraging momentum into the second half of the year.
• As a pure play enabler of CGTs globally, we are strategically aligned with the favorable secular trends, including a more favorable regulatory environment evidenced by increased therapy approvals with broadened indications, expanding geographic regions, and forward movement in the lines of treatment.
• We believe our market-leading biopreservation franchise supports more than 70% of U.S. commercial CGT trials and sets us up for a sustainable long-term and a promising future.

Industry Context

The company operates in the cell and gene therapy (CGT) market, which is experiencing favorable secular trends, including increased therapy approvals and expanding geographic regions. BioLife Solutions is positioning itself as a key enabler in this market with its biopreservation products and services.

Comparison to Industry Standards

• BioLife Solutions' focus on cell processing and biopreservation aligns with the growing demand for these services in the CGT industry.
• The company's claim of supporting more than 70% of U.S. commercial CGT trials suggests a strong market position compared to competitors like Cryoport and Thermo Fisher Scientific, who also offer biopreservation solutions.
• The sequential growth in Cell Processing revenue indicates a positive trend, which is crucial for companies in this sector.
• The increase in gross margin and adjusted EBITDA shows improved profitability, which is a key metric for investors in the biotech space.
• The updated revenue guidance suggests confidence in future performance, which is a positive signal compared to companies that maintain or lower guidance.

Stakeholder Impact

• Shareholders will likely react positively to the raised revenue guidance and improved profitability metrics.
• Employees may be encouraged by the company's positive momentum and strategic alignment with the CGT market.
• Customers will benefit from the company's continued focus on providing high-quality biopreservation products and services.
• Suppliers may see increased demand for their products as the company's business grows.
• Creditors may view the company's improved financial performance as a positive sign.

Next Steps

• Management will discuss the financial results and provide a business update during a conference call and webcast.
• The company expects 11 additional product approvals, geographic expansions, or new indications for its biopreservation media in the next 12 months.

Key Dates

Keywords

Cell Processing, Biopreservation, Cell and Gene Therapy, Biostorage, EBITDA, Revenue Guidance, Gross Margin, Financial Results, Cryopreservation, FDA Master File